Perspective Therapeutics Q3 net loss widens on higher R&D costs
CATX•Perspective Therapeutics reported a Q3 net loss of $32.44 million, or $0.27 per share, as R&D expenses increased. It ended the quarter with $202 million in cash and investments, which it expects to fund operations and clinical milestones into 2028.
1. Quarterly results
Perspective Therapeutics’ Q3 net loss widened as research and development expenses increased. The company reported a loss of $32.44 million, or $0.27 per share, and $20,000 in grant revenue.
2. Cash and clinical programs
The company ended Q3 with $202 million in cash and investments and expects those reserves to fund operations and clinical milestones into 2028. It completed enrollment in a key bamzireotide cohort and continued recruitment for its lapemelanotide and PSV359 studies.
3. Regulatory and trial plans
The FDA granted Fast Track designation to PSV359 for FAP-positive solitary fibrous tumors, while bamzireotide received European orphan designation. Perspective Therapeutics targets an end-of-Phase 2 FDA meeting for bamzireotide in the first quarter of 2027 and plans its next PSV359 clinical update in 2027.
